Analyzing AIkido Pharma (NASDAQ:AIKI) and Precigen (NASDAQ:PGEN)

AIkido Pharma (NASDAQ:AIKI) and Precigen (NASDAQ:PGEN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations and dividends.

Valuation & Earnings

This table compares AIkido Pharma and Precigen’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AIkido Pharma $10,000.00 2,863.44 -$4.18 million N/A N/A
Precigen $90.72 million 9.26 -$322.32 million ($0.88) -5.55

AIkido Pharma has higher earnings, but lower revenue than Precigen.

Risk & Volatility

AIkido Pharma has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Comparatively, Precigen has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500.


This table compares AIkido Pharma and Precigen’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
AIkido Pharma N/A -88.61% -83.62%
Precigen -300.01% -81.74% -25.69%

Institutional & Insider Ownership

0.9% of AIkido Pharma shares are held by institutional investors. Comparatively, 75.7% of Precigen shares are held by institutional investors. 4.2% of AIkido Pharma shares are held by insiders. Comparatively, 50.7% of Precigen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings for AIkido Pharma and Precigen, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AIkido Pharma 0 0 0 0 N/A
Precigen 1 1 2 0 2.25

Precigen has a consensus target price of $9.25, suggesting a potential upside of 89.55%. Given Precigen’s higher possible upside, analysts plainly believe Precigen is more favorable than AIkido Pharma.


Precigen beats AIkido Pharma on 8 of the 11 factors compared between the two stocks.

AIkido Pharma Company Profile

AIkido Pharma Inc., a biotechnology development company, focuses on developing small-molecule anti-cancer therapeutics. The company engages in the development of therapeutic drugs for the treatment of pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL). Its portfolio includes KPC-34 for the treatment of AML and ALL; and DHA-dFdC drug for the treatment of pancreatic cancer. AIkido Pharma Inc. has an artificial intelligence and machine learning research agreement with Cogia Biotech LTD. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2020. AIkido Pharma Inc. was founded in 1967 and is based in New York, New York.

Precigen Company Profile

Precigen, Inc. engages in the engineering and industrialization of biology in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. It provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control solutions; technologies for non-browning apple without the use of artificial additives; genetically engineered swine for medical and genetic research; commercial aquaculture products; and preservation and cloning technologies. The company also offers UltraVector platform that enables design and assembly of gene programs that facilitate control over the quality, function, and performance of living cells; and RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression. In addition, it provides AttSite Recombinases, which allows stable, targeted gene integration and expression; LEAP automated platform to identify and purify cells of interest, such as antibody expressing cells and stem cells; ActoBiotics platform for targeted in situ expression of proteins and peptides from engineered microbes; and AdenoVerse technology platform for tissue specificity and target selection. The company serves the health, food, energy, and environment markets. Precigen, Inc. has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Genopaver, LLC; Fibrocell Science, Inc.; Persea Bio, LLC; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Wellness. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.

Receive News & Ratings for AIkido Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIkido Pharma and related companies with's FREE daily email newsletter.